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Abstract
Background
Exome sequencing has led to the discovery of mutations in novel causative
genes for epilepsy. One such gene is EEF1A2, encoding a neuromuscular specific
translation elongation factor, which has been found to be mutated de novo in
five cases of severe epilepsy. We now report on a further seven cases, each with
a different mutation, of which five are newly described.
Methods
New cases were identified and sequenced through the Deciphering Develop-
mental Disabilities project, via direct contact with neurologists or geneticists, or
recruited via our website.
Results
All the mutations cause epilepsy and intellectual disability, but with a much
wider range of severity than previously identified. All new cases share specific
subtle facial dysmorphic features. Each mutation occurs at an evolutionarily
highly conserved amino acid position indicating strong structural or functional
selective pressure.
Conclusions
EEF1A2 should be considered as a causative gene not only in cases of epileptic
encephalopathy but also in children with less severe epilepsy and intellectual
disability. The emergence of a possible discernible phenotype, a broad nasal
bridge, tented upper lip, everted lower lip and downturned corners of the
mouth may help in identifying patients with mutations in EEF1A2.
ª 2016 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
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Introduction
The advent of family based exome sequencing has facili-
tated the discovery of de novo and/or inherited ultrarare
mutations in an increasingly large number of genes as the
cause of epilepsy. Some of these genes have quite unex-
pected cellular functions. In these cases, the burden of
proof that the mutations are causative rests not just on
the fact that they have occurred de novo, and the absence
of such mutations in unaffected individuals, but also on
the predicted effects on the protein, and whether more
than one mutation is found in the same gene (or the
same mutation is found in multiple affected individuals).
One gene in which missense mutations have recently
been reported is EEF1A2, encoding translation elongation
factor 1A2 (OMIM #602959). Elongation factor eEF1A
has a key role in protein synthesis, the delivery of amino-
acylated tRNAs to the ribosome. In addition to this role,
eEF1A has been reported to have numerous noncanonical
“moonlighting” properties, possibly by virtue of its abun-
dance in the cell, where it comprises 3% of the total pro-
tein (Condeelis 1995).
While mutations affecting such a basic housekeeping
function would at first glance seem unlikely to affect only
neurodevelopment, the specificity of the disorder is deter-
mined by the expression pattern of eEF1A isoforms. All
vertebrates have two independently encoded isoforms of
eEF1A; eEF1A1 is ubiquitously expressed throughout
development but is then switched off specifically in neu-
rons and muscle postnatally, where it is replaced by
eEF1A2 (Chambers et al. 1998; Khalyfa et al. 2003).
eEF1A2 is unique among translation factors in being tis-
sue-specific. It is expressed only in neurons and muscle,
with minor specific sites of expression in pancreatic islet
cells and enteroendocrine cells. Complete loss of function
of eEF1A2 in the mouse (via a homozygous deletion of
the promoter and first exon) causes severe neurodegener-
ation, loss of muscle bulk and death by 4 weeks (Cham-
bers et al. 1998). Mice that are heterozygous for this loss
of function mutation, on the other hand, have no gross
motor problems even at 21 months (Griffiths et al. 2012).
In humans, three distinct missense mutations in
EEF1A2 have been reported in five patients. The initial
report was in a study of individuals with severe intellec-
tual disability (ID): a Gly70Ser mutation was found in a
female with severe ID, autistic features and aggressive
behaviors. She was also reported to have myoclonic,
absence, and grand mal seizures (de Ligt et al. 2012). The
second report was in a survey of children with epileptic
encephalopathy, where the same Gly70Ser mutation was
identified in a 14-year-old boy with refractory epilepsy.
He also has limited comprehension and is nonverbal
(Veeramah et al. 2013). A third Gly70Ser mutation was
reported in a 1-year-old girl, but no clinical information
was included beyond a broad categorization as “neurolog-
ical with other systems involvement” (Yang et al. 2014).
The fourth and fifth individuals were identified in Japan;
both have autism and severe ID. One had infantile
spasms, now controlled by valproate, the other has gener-
alized tonic seizures. In addition, both girls were said to
have characteristic facial features. They each have different
missense mutations, Glu122Lys and Asp252His, respec-
tively (Nakajima et al. 2015). Two further cases of
Glu122Lys mutations have recently been described (Inui
et al. 2015).
We now report the finding of further mutations, all of
which have arisen de novo on one allele in the affected
individuals. We report on seven cases, each with a differ-
ent mutation, of which five are newly described. All are
associated with epilepsy and ID, but with a much wider
range of severity than previously suspected. We note
characteristic facial features in all patients for whom we
could obtain photos.
Methods
Ethical compliance
This study has UK Research Ethics Committee approval
(10/H0305/83, granted by the Cambridge South REC, and
GEN/284/12 granted by the Republic of Ireland REC).
Recruitment
Patients were recruited through personal communication
with clinicians, via a website (http://eef1a2epilepsy.word-
press.com/) and from the Deciphering Developmental
Disorders (DDD) project (http://www.ddduk.org/). A pro
forma was designed and sent to clinicians; where possible
this was used in conjunction with the information depos-
ited in DDD.
Sequencing and analysis
Trio-based exome sequencing was performed as part of
the DDD study as previously described (Deciphering
Developmental Disorders 2015; Wright et al. 2015). In
brief, target capture using Agilent SureSelect 55 MB
Exome Plus was performed on saliva- or blood-derived
genomic DNA from each affected individual and their
parents and sequenced on Illumina HiSeq. DeNovoGear21
was used to identify de novo sequence variants and
Ensembl Variant Effect Predictor (VEP version 2.6, http://
www.ensembl.org/info/docs/tools/vep/index.html) was
used to predict the effect of each genomic variant.
PolyPhen-2 analysis was carried out at http://genet
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ics.bwh.harvard.edu/pph2/. SIFT analysis was carried out
at http://sift.bii.a-star.edu.sg/www/SIFT_seq_submit2.html
(parameters used: Database UniProt-SwissProt2010_09;
Median conservation of sequences 3.00; Remove
sequences more than 90% identical). Genbank accession
for EEF1A2 is NM_001958.3.
Results
Clinical findings/case studies
Case 1
Case 1 is a 3-year-old girl born after a normal pregnancy
at 38 weeks, weighing 3.72 kg (75th centile). She developed
seizures at age 2 months and was diagnosed with an
epileptic encephalopathy. Initially she had very frequent
myoclonic and tonic-clonic seizures and later developed
absence seizures. Her EEG showed multifocal and occa-
sional generalized discharges. After starting sodium val-
proate at age 2 years, her seizure frequency has decreased
to 1–2 per day. She has global developmental delay, hypo-
tonia and dysphagia. She is unable to walk. She has a small
hemangioma on her left temple, for which there is a family
history on the mother’s side, and her head circumference
was 46.5 cm at 9 months (91st centile) but no particular
dysmorphisms were noted. She was found to have a
heterozygous constitutive c.208G->A (p.G70S) mutation in
EEF1A2 that was not detected in either parent.
Case 2
Case 2 is a 9-year-old boy born by emergency Cesarean sec-
tion at 42 weeks after an uncomplicated pregnancy, weigh-
ing 4.45 kg (98th centile). His mother has a history of
epilepsy but was not taking anticonvulsants during preg-
nancy. He was described as a passive baby and now has sev-
ere global developmental delay and seizures. He did not sit
independently until 13 months or walk until over 5 years.
He does not speak recognizable words but uses signs to
communicate his needs. He was reported to have brachy-
cephaly, widely spaced teeth, an everted lower lip and head
circumference of 52 cm at 5 years (>25th centile). He was
found to have a heterozygous constitutive c.211A->C
(p.I71L) mutation in EEF1A2 not detected in either parent.
Case 3
Case 3 is a 14-year-old girl born after a normal pregnancy
at 37 weeks, weighing 2.81 kg (25th centile). There was
initial poor weight gain and she had three hospital admis-
sions in the first year with pulmonary infections. Develop-
mental delay was identified from 8 months, with delay in
motor milestones; she only sat from 14 months. Seizure
onset was at age 2 years, sometime after her developmen-
tal delay was first noted. The seizures were characterized
by head drops which then evolved to eye rolling and arm
extension occurring in clusters reminiscent of infantile
spasms. She has continued to have seizures which have
been resistant to medication. Head circumference mea-
sured at age 8.75 years was 51.5 cm (<50th centile). She is
still unable to walk independently and has no speech. She
has brachycephaly with small wide-spaced teeth. She is
generally hypotonic and has cold peripheries. She now has
reduced bone density with fractures and thoracolumbar
scoliosis. She was found to have a heterozygous de novo
constitutive c.271G->A (p.D91N) mutation in EEF1A2.
Case 4
Case 4 is a 9-year-old girl who was born weighing 3.86 kg
(>75th centile). She had focal seizures as an infant but now
has myoclonic, tonic, and occasional tonic-clonic seizures,
occurring daily. She has severe hypotonia and severe global
delays. She has no head control, no ability to grasp objects,
is nonverbal and unable to sit or bear weight on legs. She
has very poor bone density. Her head circumference was
43.6 cm at 6 months (<75th centile), and 50 cm at 6 years
(>2nd). She was found to have a heterozygous de novo
c.292T->C (p.F98L) mutation in EEF1A2.
Case 5
Case 5 is a 6-year-old girl born after a normal pregnancy
at 41 weeks, weighing 3.43 kg (50th centile). Hypotonia
was noted during the neonatal period with subsequent
gross motor delay. She sat unsupported at 15 months and
walked independently from 4 years. She has no speech
but vocalizes and uses signs. Seizures developed at
10 weeks as jerky, stiffening of legs several times a week,
which then developed to include head nodding. Her
symptoms improved on commencement of sodium val-
proate. An initial EEG at 10 months was normal but
showed spikes and polyspikes with some slow wave activ-
ity at 21 months. She was described to have downslanting
and slightly short palpebral fissures, a broad forehead and
a broad, flat nasal bridge with downturned corners of the
mouth and head circumference below the 2nd centile. She
was found to have a heterozygous de novo constitutive
c364G->A (p.E122K) mutation in EEF1A2.
Case 6
Ten-year-old girl born at 40 weeks by planned Cesarean
section weighing 3.69 kg (<75th centile). Initial gross and
fine motor development was normal but only walked
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independently at 2 years. No evidence of hypotonia.
Speaks in sentences, with significant delays in language
and comprehension but pleasant and friendly; in main-
stream primary but will go to special school at secondary
level. Gait and coordination immature but essentially nor-
mal. Seizures commenced at 3 months, and were initially
myoclonic seizures. She then developed absence seizures
at the age of 2 years which are now controlled by val-
proate and lamotrigine. EEG shows slow background
rhythms and generalized epileptic discharges. Her MRI
brain is normal. Head circumference 51 cm at 5.2 years
(25th centile). Broad base nose, prominent midface and
thin upper lip but normal eyes. Found to have heterozy-
gous de novo constitutive c.370G->A (p.E124K) mutation
in EEF1A2.
Case 7
Case 7 is a 5-year-old boy born at 41 weeks by Cesarean
section for decreased fetal heart rate weighing 2.80 kg (9th
centile) following an uncomplicated pregnancy. Family his-
tory negative for seizures or developmental concerns in
either parent, but the boy has a maternal uncle with devel-
opmental delays who is able to live independently. Devel-
opmental history notable for sitting with support at
18 months and currently he does not walk, has no speech,
and is able to help feed himself. Past medical history signifi-
cant for food allergies, eosinophilic esophagitis, and pan-
creatitis. He is frequently irritable and uncomfortable – he
cries and grinds his teeth, kicking his legs and flapping his
hands. He has choreic movements and disturbed sleep
which responds partially to melatonin. His first seizure was
at 4 months and was characterized by rightward eye devia-
tion and right limb motor activity. Initial EEG was abnor-
mal and brain MRI abnormal due to mild hypoplasia of
corpus callosum and mild global volume loss (that is pro-
gressive on subsequent MR neuroimaging). He started phe-
nobarbital and had no further seizures until 6 months old
when he developed infantile spasms. Despite multiple
rounds of ACTH/steroids and multiple anticonvulsant tri-
als he continues to have seizures of multiple types including
isolated epileptic spasms, myoclonic, myoclonic-tonic,
tonic, and tonic-clonic seizures. His head circumference
was 50 cm at 5 years (>25th centile). This boy was found
to have a heterozygous de novo c.1267 C>T (p.R423C)
mutation in EEF1A2. The clinical findings are summarized,
together with those in previous reports, in Table 1.
All the mutations are missense, and have arisen de novo.
Each of the individuals identified as having a mutation in
EEF1A2 has experienced repeated seizures, and in some
cases they now have intractable epilepsy. Almost all show
global developmental delay and hypotonia, but one
individual, case 6, is clearly much less severely affected than
the others. She has much milder but still moderate ID, and
has had no seizures for a number of years.
In contrast to the previously published cases, none of the
individuals we report has been diagnosed with autism.
Head circumference is frequently, but not invariably,
affected, but in the absence of longitudinal data it is hard to
know whether this could be associated with specific muta-
tions, or whether it varies with age. Gait abnormalities have
been reported in the two individuals with E122K muta-
tions, and one of the children with a G70S mutation. It is
impossible to tell whether this would be consistently associ-
ated with mutations in EEF1A2, or only with specific muta-
tions, as many of the patients are unable to walk. Other
individuals have previously undescribed features like food
allergies and reduced bone density.
Apart from case 2, we were able to obtain photographs
of all the children reported here (Fig. 1). We examined
these, along with reports from their clinicians, to establish
whether the features reported in the two girls described by
Nakajima et al. (2015) were seen consistently, to establish a
possible dysmorphic phenotype for patients with EEF1A2
mutations. The features which were common in the origi-
nal two patients were deep set eyes, epicanthus, depressed
nasal bridge, tented upper lips with high arch palate and an
everted lower lip. Of our seven patients only three had any
remarks with regards to possible dysmorphisms and there
were no commonalities among the descriptions. However,
on examination of the photographs it is possible to see cer-
tain distinct features emerging. Table 2 shows a summary
of the facial features seen in our patients together with
those described in Nakajima et al. (2015). The epicanthus
and depressed nasal bridge described by Nakajima et al.
(2015) are most likely due to ethnic origins, since these are
not seen or described in our patients except in case 3 and
case 5, respectively. A more common finding is a broad
nasal bridge. The lower facial features were more consistent
with 5/6 of our patients displaying a tented upper lip and
eversion of their lower lip, associated with downturned cor-
ners of mouth. This is clearly demonstrated in cases 1, 3,
and 5 and more subtly in cases 4 and 7 (Fig. 1). None of
our patients were reported to have abnormal palates. Addi-
tional features which may be of significance are full cheeks,
which have been mentioned by Nakajima et al. (2015), and
large ears, but these are difficult to fully quantify given the
modest numbers of cases and absence of detailed measure-
ments.
Predicted effects of the mutations on the
protein
All the known mutations are missense, changing a single,
highly conserved, amino acid. Table 3 lists all changes
found at the DNA and protein level, together with the
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predicted effect of each amino acid substitution on the
eEF1A2 protein.
Each of these mutations is strikingly conserved
throughout evolution. Although the specific EEF1A2 iso-
form seen in neurons is not found in species lower than
vertebrates, genes encoding EF1alpha are seen in all life
forms. If we use all isoforms for comparison, therefore,
the amino acids that are mutated in five cases are
strictly conserved throughout evolution to E.coli, and the
remaining three are conserved in yeast (S. cerevisiae,
Fig. 2). This dramatic level of conservation clearly sug-
gests strong selective pressure and functional conse-
quences of mutating any one of these amino acids.
Discussion
We have identified a series of further novel de novo mis-
sense mutations in EEF1A2 in patients with epilepsy, and
thus build on the recently expanding evidence implicating
EEF1A2 as a key player in a subset of related neurological
syndromes.
None of the mutations is seen in the Exome Aggrega-
tion Consortium (ExAc) database that contains data from
over 60,000 individuals. Indeed, EEF1A2 has been identi-
fied as one of the top thousand genes in the human gen-
ome considered to be subject to excessive constraint
(Samocha et al. 2014); there are no known coding
Table 1. Summary of phenotypic characteristics seen in each case with a missense mutation in EEF1A2.
Protein
change Epilepsy Autism
SID/delay/motor
delay Hypotonia
Facial
features
noted Other Reference
Gly70Ser Myoclonic seizures,
grand mal, absences
Yes Global
developmental
delay, SID
Yes No Normal head circumference
at 22 years
de Ligt et al. 2012
Gly70Ser Infantile spasms,
then myoclonic,
refractory
NR Non-verbal Yes NR Acquired microcephaly
<2nd centile, gait instability
Veeramah et al. 2013
Gly70Ser Epileptic
encephalopathy
NR Global
developmental
delay
Yes Yes No microcephaly at
9 months, dysphagia
Yang et al. 20141
This study, case 1
Ile71Leu Seizures NR Global
developmental
delay
NR Yes Head circumference
>9th centile, brachycephaly
This study, case 2
Asp91Asn Head drops, then
infantile spasms.
Continued head
drops and atypical
absences
NR Global
developmental
delay.
Non-verbal
Yes Yes Head circumference
<50th centile. Brachycephaly.
Reduced bone density
with fractures
This study, case 3
Phe98Leu Focal seizures as
infant, now
myoclonic, tonic
and occasional
tonic-clonic
No Global
developmental
delay
Yes Yes Head circumference
85th centile at 6 months,
Reduced bone density.
This study, case 4
Glu122Lys Infantile spasms,
controlled
No Non-verbal, gross
motor delay
Yes Yes Head circumference
<2nd centile at
5 years, unsteady gait
This study, case 5
Glu122Lys Infantile spasms,
controlled
Yes Yes Yes Yes Small head circumference
at birth, cerebral atrophy,
ataxic gait
Nakajima et al. 2015
Glu124Lys Myoclonic seizures
from 3 months
Absences from
2 years, controlled
No Significant delays
in language
but speaks in
sentences
No No Head circumference
25th centile at 5 years,
gait immature but
essentially normal
This study, case 6
Asp252His Generalized tonic
seizures, controlled
Yes Yes Yes Yes Small head circumference
at birth, cerebral atrophy
Nakajima et al. 2015
Arg423Cys Multiple daily seizures,
intractable
NR Global
developmental
delay
Yes Yes Head circumference
25th centile at 4 years,
multiple food allergies
This study, case 7
1Categorised under “Patients with Neurologic Plus Other Organ System Disease Phenotype” in Yang et al.
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polymorphisms. It is also noteworthy that a spice site
mutation in EEF1B2 that encodes eEF1Ba, the GTP
exchange factor for eEF1A, was detected in a consan-
guineous family with nonsyndromic intellectual disability
(Najmabadi et al. 2011), highlighting the importance of
this pathway for cognitive and neurological disorders.
All the mutations we identified are likely to impact on
the structure or function of the protein according to
either PolyPhen, SIFT analysis, or both. With the excep-
tion of R423C, all mutations in eEF1A2 are solvent acces-
sible and located at or adjacent to known binding sites
from yeast or rabbit structural or mutagenesis data. The
R423C mutation is buried at the interdomain junction of
the protein and is thus likely to have consequences for
the protein structure or conformation.
The two cases with E122K mutations may suggest a
possible mechanism by which mutations in EEF1A2 cause
neuronal dysfunction, as the equivalent mutation in yeast
was serendipitously characterized many years ago, and
found to result in translational infidelity (Sandbaken and
Culbertson 1988). The two children with E122K muta-
tions both have an ataxia gait; ataxia has also been seen
in individuals with mutations in genes encoding other
proteins that are involved in the control of translational
Figure 1. Facial dysmorphologies in five of the cases reported in this study.
Table 2. Dysmorphological facial features seen in individuals with mutations in EEF1A2.
Nakajima et al. (2015)
Case 1 Case 3 Case 4 Case 5 Case 6 Case 7Patient 1 Patient 2
Deep set eyes + +     + 
Epicanthus +  +    
Depressed nasal bridge + +    +  +
Broad nasal bridge + + + + + + + +
Tented upper lip + + + + + + n.a. +
High palate + +      
Everted lower lip + + + + + + n.a. +
Downturned corners of mouth + + + + + + n.a. +
n.a., not able to be assessed.
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fidelity, including a missense mutation in eEF2 that
underlies spinocerebellar ataxia SCA26 (Hekman et al.
2012). In addition, a mutation in an editing-defective
form of alanyl tRNA synthetase causes ataxia and neu-
rodegeneration in mouse (Lee et al. 2006), and mutations
in the gene encoding glutamine tRNA synthetase cause
microcephaly and intractable epilepsy (Zhang et al. 2014).
Whether similar molecular defects are seen in neurons of
children with other mutations in EEF1A2 is as yet
unknown.
The newly discovered E124K mutation is of particular
interest. With the caveat that it is seen in a single case
(case 6) it clearly has the least severe clinical effect, with
the child concerned having coped in mainstream school
(albeit with moderate ID) until recently. This site is
highly conserved, but does not appear to overlap com-
pletely with known binding sites for eEF1B or GTP
(Soares et al. 2009). Children with less severe ID may be
under represented in research cohorts used for exome
sequencing analysis; in this case, the presentation of epi-
lepsy in the neonatal period, which resolved only to
remerge later in childhood, was one of the reasons for
exome sequencing having been performed. It is possible,
therefore, that there are other mutations in EEF1A2
underlying many more cases of mild ID. With only a sin-
gle case, however, it is impossible to know whether the
less severe phenotype relates to the precise mutation, or
whether there is underlying mosaicism. Indeed, this caveat
applies to all cases described so far, as all have arisen de
novo. Until more individuals with repeats of the same
mutation have been found, this issue cannot be resolved.
The original case described with a mutation in EEF1A2
was said to have “no evident facial dysmorphic features,”
calling into question whether the characteristic features
suggested by Nakajima et al. (2015) to be part of a new
“EEF1A2 syndrome” would necessarily apply in all cases,
or be mutation dependent, or even a chance finding. Cer-
tainly of our seven patients, in only three cases were there
any dysmorphisms noted. Following a careful review of
all the photographs in cases for which we could obtain
images, we conclude that indeed, there are subtle but
characteristic features in common between all the individ-
uals except case 6 (the child with the otherwise mild phe-
notype). The features seen in the cases we describe are
consistent with those described by Nakajima et al., and
include a broad nasal bridge, a tented upper lip and an
everted lower lip associated with downturned corners of
the mouth. It would be interesting to establish in humans
the timing of the switch between eEF1A1 and eEF1A2
that occurs at ~3 weeks in rodents, and relate this to
craniofacial development.
Autism has been reported in some individuals but not
others. Until more cases are discovered, so that we can
study more individuals with a specific given mutation, it
will be impossible to judge whether a finding of autism is
mutation dependent, or whether in fact individual
stochastic differences are more significant than which
amino acid has been mutated. Furthermore, patients with
more severe intellectual disability may not meet the crite-
ria for a diagnosis of autism.
The key question that remains is whether these muta-
tions represent loss of function, or gain of function/domi-
nant negative. No nonsense mutations or deletions have
ever been detected in humans. While this could be
because they are incompatible with life, the fact that mice
with a heterozygous null mutation survive normally with
no apparent physiological defects (Griffiths et al. 2012)
might suggest that loss of function mutations in humans
Table 3. Summary of changes found in EEF1A2 by exome sequencing in individuals with epilepsy/SID.
Protein
change
DNA
change No. cases
PolyPhen-2 prediction; HumDiv/HumVar
score (Benign 0 to Probably Damaging 1)
SIFT prediction; Probabilities
<0.05 are predicted to be
deleterious
Location with respect to known
binding sites, or functional data2
G70S1 G208A 3 Probably damaging; 0.998/0.980 Affect protein function; 0.00 Close to eEF1B binding site
I71L1 A211C 1 Possibly damaging; 0.864/0.995 Affect protein function; 0.00 Close to eEF1B binding site
D91N1 G271A 1 Probably damaging; 1.000/0.978 Affect protein function; 0.00 Overlaps eEF1B binding site
F98L1 T292C 1 Benign; 0.138/0.145 Affect protein function; 0.00 Overlaps eEF1B binding site
E122K1 G364A 2 Probably damaging; 1.000/0.999 Tolerated; 0.16 Affects translational fidelity in yeast;
close to GTP/GDP-binding site
E124K1 G370A 1 Benign; 0.101/0.072 Affect protein function; 0.03 No direct overlap with known
binding sites but close to
GTP/GDP-binding site
D252H G754C 1 Probably damaging; 0.962/0.980 Affect protein function; 0.00 Overlaps eEF1B binding site
R423C1 C1267T 1 Benign; 0.054/0.092 Affect protein function; 0.00 Buried
1Reported in this study, in bold = reported for the first time.
2Based upon experimental structural and/or functional data of equivalent amino acid residue in yeast eEF1A (Sandbaken and Culbertson 1988;
Andersen et al. 2001; Soares et al. 2009; Crepin et al. 2014).
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have not been detected because they do not give rise to
overt disorders. However, the lack of polymorphisms in
EEF1A2 would argue against this explanation, so perhaps
loss of function is simply better tolerated in mice, at least
in terms of seizures and muscle function (since grip
strength in heterozygous null mice is unaffected right up
to 21 months, the oldest age of testing). This might sug-
gest that the missense mutations in humans cause a gain
Figure 2. Evolutionary conservation of amino acids mutated in EEF1A2 in individuals with epilepsy.
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of function, or dominant negative effect – further cases,
or study of the mutations in animal models, will be
needed to resolve these issues.
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